Search Results
Your search for A matches 33679 pages
Showing 17001 - 17050Cabozantinib in Advanced Hepatocellular Cancer: Call for Revision of Practice Standards
As reported in The New England Journal of Medicine by Ghassan K. Abou-Alfa, MD, and colleagues, and reviewed in this issue of The ASCO Post, the phase III CELESTIAL trial has demonstrated that cabozantinib (Cabometyx) improved the median overall survival to 10.2 months in comparison to 8 months...
Cabozantinib Improves Survival in Patients With Previously Treated Hepatocellular Carcinoma
As reported in The New England Journal of Medicine by Ghassan K. Abou‑Alfa, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, the second interim analysis of the phase III CELESTIAL trial has shown a significant improvement in overall and progression-free survival with cabozantinib...
Nivolumab Plus Ipilimumab in Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 16, 2018, nivolumab (Opdivo) and ipilimumab...
Fadlo R. Khuri, MD, FACP, Acknowledged With IASLC Lifetime Scientific Achievement Award
Oncologist, physician, and Professor, Fadlo R. Khuri, MD, FACP, has been recognized by the International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto. Dr. Khuri received the Joseph W. Cullen...
Novel Treatment Approaches in Early Relapse of Follicular Lymphoma
“Patients with follicular lymphoma who relapse early after treatment are a minority of patients, fortunately, but they are clearly patients with a different disease,” according to Jonathon B. Cohen, MD, of Emory University School of Medicine. At Emory’s 2018 Debates and Didactics in Hematology and...
Jean-Charles Soria, MD, PhD, Receives 2018 ESMO Award
The European Society for medical oncology (ESMO) has granted the 2018 ESMO Award to Jean-Charles Soria, MD, PhD, an international lung cancer expert and pioneer in the development of anticancer drugs. The award was founded in 1985 to acknowledge an ESMO member who has made contributions to the...
Next-Generation Sequencing: New Technology That Requires Further Thought
Next-generation sequencing is used with increasing frequency to provide essential information about a patient’s diagnosis and treatment. In recent months, the U.S. Food and Drug Administration (FDA) has approved several new next-generation sequencing diagnostic tools, and the Centers for Medicare...
Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on TNBC: Combination Immune Checkpoint Inhibitor Therapy
Lisa A. Carey, MD, of the University of North Carolina, and Sherene Loi, MD, PhD, of the Peter MacCallum Cancer Centre, discuss the phase III IMpassion 130 trial testing the first-line combination of the PD-L1 inhibitor atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer...
ESMO 2018: SOLAR-1: Alpelisib in Patients With PIK3CA-Mutated HR-Positive, HER2-Negative Advanced Breast Cancer
Targeting a common mutation in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib improved progression-free survival, according to...
ESMO 2018: PALOMA-3: Palbociclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Treatment with the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (Ibrance) achieved a clinically meaningful improvement in overall survival in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer that has relapsed or ...
ESMO 2018: IMpassion 130: Atezolizumab Plus Nab-Paclitaxel in Metastatic Triple-Negative Breast Cancer
A combination of immunotherapy and chemotherapy improves survival in some patients with metastatic triple-negative breast cancer, according to late-breaking results from the IMpassion130 trial reported by Schmid et al at the European Society for Medical Oncology (ESMO) 2018 Congress (Abstract...
ESMO 2018: HDAC Inhibitor Therapy in Advanced Hormone Receptor–Positive Breast Cancer
A phase III trial presented by Jiang et al at the European Society for Medical Oncology (ESMO) 2018 Congress showed activity of histone deacetylase (HDAC) inhibitor therapy in advanced hormone receptor–positive breast cancer (Abstract 283O_PR). Endocrine therapies are the foundation of...
Karl Lewis, MD, on Basal Cell Carcinoma: An Ongoing Study
Karl Lewis, MD, of the University of Colorado, discusses a phase II study of cemiplimab in patients with advanced basal cell carcinoma who experienced progression of disease on, or were intolerant of, prior hedgehog pathway inhibitor therapy.For more information about this ongoing trial, visit...
Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy and Targeted Treatments
Johan F. Vansteenkiste, MD, PhD, of Catholic University Leuven, summarizes a session he co-chaired that included discussion of translating advances in stage IV disease to nonmetastatic lung cancer, TKI approaches in early-stage disease, and integrating immunotherapy and TKIs in stage III disease...
Margaret Foti, PhD, MD (hc), Receives 2018 ESMO Women for Oncology Award
The European Society for Medical Oncology (ESMO) has recognized Margaret Foti, PhD, MD (hc), with the 2018 ESMO Women for Oncology Award. The award recognizes an ESMO member who has contributed to supporting the career development of women in oncology. The recipient must have actively worked to...
Current Treatment Landscape of Relapsed or Refractory Chronic Lymphocytic Leukemia
Novel agents such as ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (Venclexta) have transformed the treatment of chronic lymphocytic leukemia (CLL) and are increasingly used to treat the disease. The optimal sequencing of these agents is not clear in relapsed or refractory disease,...
Expert Point of View: Antoinette Wozniak, MD
Formal discussant Antoinette Wozniak, MD, of UPMC Hillman Cancer Center, Pittsburgh, said, “KEYNOTE-407 is a very positive trial, showing improved overall and progression-free survival with the addition of pembrolizumab (Keytruda) to standard chemotherapy.” In her opinion, evidence from this and...
Regardless of Taxane Used, Pembrolizumab Plus Chemotherapy Improves Survival in Squamous NSCLC
The addition of pembrolizumab (Keytruda) to a standard platinum doublet as first-line therapy improved overall and progression-free survival in patients with metastatic squamous non–small cell lung cancer (NSCLC), in the primary analysis of KEYNOTE-407.1,2 Furthermore, it did not seem to matter...
Entrectinib Shows Activity in ROS1-Positive NSCLC
Although ROS1-mutated lung cancer accounts for about 1% to 2% of all non–small cell lung cancers (NSCLCs), it is an important druggable oncogene, and new data show that it can be successfully targeted for clinical gain. In a pooled analysis of phase I and II trials in patients with ROS1-positive...
Expert Point of View: John K. Field, PhD, FRCP
“This wonderful result joins other landmark studies. The differential effect by gender is extremely important,” said formal discussant of the trial, John K. Field, PhD, FRCP, of the University of Liverpool, UK. “This study validates the management protocol and analysis of nodule volume and growth...
NELSON Trial: ‘Call to Action’ for Lung Cancer CT Screening of High-Risk Individuals
Results of the very large, randomized, population-based NELSON trial confirm the value of low-dose computed tomography (CT) screening in people at high risk for developing lung cancer. The protective value of screening was more pronounced in women than in men. These study findings were presented at ...
Expert Point of View: Everett Vokes, MD
“PACIFIC is a positive trial, with a 32% improvement in survival, and maintenance durvalumab is a new standard of care,” stated formal discussant Everett Vokes, MD, Chair of the Department of Medicine at the University of Chicago and a pioneer in the concurrent use of chemotherapy and radiotherapy ...
Durvalumab Improves Overall Survival in Unresectable Stage III NSCLC
Several lung cancer trials have shown prolonged progression-free survival with checkpoint inhibitor therapy. For the first time, the phase III PACIFIC trial has found an overall survival benefit for the selective programmed cell death ligand 1 (PD-L1) checkpoint inhibitor durvalumab (Imfinzi) vs...
Cancer Care in the Palestinian Territories
The global burden of cancer is huge and growing. In 2018, there will be > 18 million new cancer cases and 9.6 million deaths.1,2 Although several recent articles have reviewed cancer in developing countries, few have focused on the Palestinian territories. There are several reasons for that,...
How the Nobel Prize Could Spur More Cancer Advances
Even before James P. Allison, PhD, made an appearance at the Fourth International Cancer Immunotherapy Conference: Translating Science Into Survival in New York City, the excitement among attendees was palpable. Earlier that day, October 1, 2018, Dr. Allison and Tasuku Honjo, MD, PhD, of Kyoto...
Expert Point of View: Hossein Borghaei, MS, DO
Formal discussant, Hossein Borghaei, MS, DO, of Fox Chase Cancer Center, was guardedly optimistic about the IMpower132 trial results. “The study met its primary endpoint, and investigator-assessed progression-free survival was superior in the investigational arm. Overall survival was not mature,...
Atezolizumab Plus Standard Chemotherapy Improves Progression-Free Survival in Stage IV NSCLC
The combination of atezolizumab (Tecentriq), a programmed cell death ligand 1 (PD-L1) inhibitor, plus carboplatin or cisplatin and pemetrexed (Alimta) as first-line therapy followed by pemetrexed plus atezolizumab maintenance therapy improved progression-free survival in patients with stage IV...
Paolo A. Ascierto, MD, on Melanoma: Acute and Chronic Toxicities
Paolo A. Ascierto, MD, of Istituto Nazionale Tumori–Fondazione Pascale, discusses the breakthroughs in melanoma treatment and the challenges of managing toxicities, especially endocrine and neurologic side effects, which can require lifetime hormone replacement and may cause permanent dysfunction.
ESMO 2018: Variations Between European Countries in Time to Reimbursement Decisions for New Cancer Treatments Approved by the EMA
Some European countries take more than twice as long as others to reach health technology assessment (HTA) decisions to reimburse new cancer treatments following their approval by the European Medicines Agency (EMA). The average decision time is longer than 1 year in some countries, according to a...
ESMO 2018: Pooled Analysis of Influence of Sex on Chemotherapy Efficacy and Toxicity in Esophagogastric Cancer
In an analysis presented by Davidson et al at the European Society for Medical Oncology (ESMO) 2018 Congress (Abstract 619PD_PR), data were pooled from four UK randomized controlled clinical trials of first-line chemotherapy in esophagogastric cancer, finding significant differences in a...
ESMO 2018: About 1 in 6 Premenopausal Patients With Early Breast Cancer Do Not Adhere to Adjuvant Endocrine Therapy
Nearly 1 in 6 premenopausal women being treated for early-stage breast cancer do not adhere adequately to tamoxifen therapy after 1 year of treatment, potentially putting themselves at increased risk of recurrence and reduced survival, reported a French prospective study at the European Society for ...
ESMO 2018: Short-HER Trial Examines Abbreviated Course of Trastuzumab in Some HER2-Positive Early Breast Cancers
Women with HER2-positive early breast cancer with small tumors have similar disease-free survival and lower risk of cardiac toxicity with a 9-week course of adjuvant trastuzumab (Herceptin) compared to those treated for 1 year, according to a subgroup analysis of the Short-HER trial reported by...
Adoptive T-Cell Therapy for Progressive Multifocal Leukoencephalopathy
An emerging treatment known as adoptive T-cell therapy has proven effective in a phase II clinical trial for treating progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection sometimes observed in patients with cancer and other diseases in which the immune...
Genomic Classification of Myeloproliferative Neoplasms and Integration in Predictive Models
In a study reported in The New England Journal of Medicine, Grinfeld et al identified distinct genomic subgroups among patients with myeloproliferative neoplasms that, when combined with clinical variables, offered the potential for individualized predictions of clinical outcomes. Study Details...
Adjuvant Chemotherapy in High-Grade Uterine Leiomyosarcoma
As reported in the Journal of Clinical Oncology by Hensley et al, a phase III NRG Oncology/Gynecologic Oncology Group study assessing adjuvant chemotherapy vs observation in disease-free patients with uterus-confined high-grade leiomyosarcoma was stopped due to accrual futility; available data...
Regular Aspirin Use and Reduction in Risk for Hepatocellular Carcinoma
A pooled analysis of two large U.S. prospective cohort studies reported in JAMA Oncology by Simon et al indicates that regular use of aspirin is associated with a significant reduction in risk for hepatocellular carcinoma (HCC), with an apparent dose- and duration-dependent effect. Study Details...
Established, Modifiable Cancer Risk Factors
According to a new American Cancer Society report published by Gapstur et al in CA: A Cancer Journal for Clinicians, the highest priority in a national cancer control plan is the expansion of tobacco control—the intervention with the largest potential health benefits. This report is the...
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma
In an analysis of two Nordic Lymphoma Group trials with long-term follow up reported in the Journal of Clinical Oncology, Lockmer and colleagues found evidence that many patients receiving rituximab (Rituxan) as initial treatment for advanced indolent lymphoma may not require the addition of...
Utility of FDG-PET for Residual Lesions After Chemotherapy for Metastatic Seminoma
In an analysis of International Global Germ Cell Cancer Group Registry data reported in the Journal of Clinical Oncology by Cathomas et al, fluorodeoxyglucose positron-emission tomography (FDG-PET) was found to have a low positive predictive value for vital tumor in residual lesions after...
ICU Admissions During Terminal Hospitalizations in Patients With Stage IV Lung Cancer
In a study reported in the Journal of Oncology Practice, Mrad et al found an increase in the proportion of patients with stage IV lung cancer admitted to the intensive care unit (ICU) during terminal hospitalization between 1998 and 2014. A large increase in palliative care contacts also occurred,...
FDA Approves Talazoparib for Deleterious Germline BRCA-Mutated HER2-Negative Locally Advanced or Metastatic Breast Cancer
On October 16, 2018, the U.S. Food and Drug Administration (FDA) approved talazoparib (Talzenna), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer....
Small Study of Neoadjuvant Combination Checkpoint Blockade in High-Risk Stage III Melanoma
Neoadjuvant combination checkpoint blockade showed activity among patients with high-risk stage III melanoma in a small study. However, a high incidence of side effects caused the trial to be closed early. These results were published by Amaria et al in Nature Medicine. The phase II...
Study Finds Deep Learning Can Distinguish Recalled-Benign Mammogram Images From Malignant and Negative Cases
Although digital mammography is effective in detecting early-stage breast cancer and in reducing mortality, high recall rates after a screening mammogram often result in unnecessary medical procedures, including breast biopsies, medical costs, and psychological stress for patients. A...
FDA Accepts New Drug Application, Grants Priority Review to Selinexor for Pentarefractory Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has accepted a new drug application seeking accelerated approval for selinexor, a first-in-class, oral selective inhibitor of nuclear export (SINE) compound, as a new treatment for patients with pentarefractory multiple myeloma. The FDA...
Opioid Use Following Video-Assisted Thoracoscopic Surgery or Open Resection in Early-Stage Lung Cancer
In a study reported in a research letter in JAMA Oncology, Tuminello et al found that video-assisted thorascopic surgery (VATS) was less likely than open resection to be associated with long-term opioid use in patients undergoing surgery for early-stage lung cancer. Study Details The study...
Duvelisib vs Ofatumumab in Relapsed or Refractory CLL/SLL
As reported in the journal Blood by Flinn et al, the phase III DUO trial has shown significantly prolonged progression-free survival with the phosphoinositide 3-kinase (PI3K)-δ,-γ inhibitor duvelisib (Copiktra) vs ofatumumab (Arzerra) in patients with relapsed or refractory chronic...
ESMO 2018: Patients With Breast Cancer Use Twitter as a Nonmedical Forum to Share Experiences
Twitter is a place where many patients with cancer go to share and discuss their experiences of the disease, according to a recent exploratory study to be presented by Sánchez-Bayona et al at the European Society for Medical Oncology (ESMO) 2018 Congress (360P_PR). The...
ESMO 2018: Precision Cancer Care Moves to Community Setting
Nearly 1 in 4 patients with advanced cancer treated at a community practice cancer network in the United States received innovative drugs matched to DNA mutations in their tumors. These results, to be reported by Alvarez et al at the European Society for Medical Oncology (ESMO) 2018 Congress...
Adherence to Endocrine Therapy for Breast Cancer in Black Women and White Women
In a study reported in the Journal of the National Cancer Institute, Wheeler et al found that black women reported nonadherence to endocrine therapy for breast cancer more often than white women, although no significant difference in discontinuation of treatment was observed. The study...
Assessment of the 8th Edition of the AJCC TNM Staging System in Cohort With Resected Pancreatic Cancer
In a study reported in JAMA Surgery, van Roessel et al found that the recently released 8th edition of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system for pancreatic cancer provided better distribution among cases and some increase in prognostic...
